LivingGLP1
Study S003204

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Japanese Participants With Overweight or Obesity (AMAZE 10)

Registration

Registration
NCT07822061
Acronym
AMAZE 10
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
QUADRUPLE
Status
RECRUITING
Enrollment
400
Start
2026-09-07
Primary completion
2029-02-05
Lead sponsor
Novo Nordisk A/S
Conditions
Overweight; Obesity
Interventions
DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1313-7707

Registered primary outcomes

  • Relative change in body weight [From baseline (week 0) to week 84]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.